Loading...
•
Jun 30, 2023
Ionis Q2 2023 Earnings Report
Ionis' revenue increased due to partnered programs, and progress was made in advancing its pipeline and preparing for product launches.
Key Takeaways
Ionis Pharmaceuticals reported a revenue increase of 40% compared to Q2 2022, driven by partner payments. The company is advancing its pipeline, with investments in eplontersen, olezarsen, and donidalorsen. They have a strong cash position of $2.4 billion.
Revenue increased by 40% compared to Q2 2022, driven by significant partner payments.
Operating expenses increased due to investments in advancing the pipeline and preparing for product launches.
Cash and short-term investments reached $2.4 billion, enabling continued investments.
Late-stage pipeline includes eight medicines for 10 indications, highlighted by eplontersen.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.comCollaborative agreements Revenue
CapyFin.com Forward Guidance
Ionis is on track to achieve its 2023 guidance, with substantial revenue and a strong balance sheet supporting investments in key opportunities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income